C
Cinta Pallares
Researcher at Hospital de Sant Pau
Publications - 24
Citations - 6053
Cinta Pallares is an academic researcher from Hospital de Sant Pau. The author has contributed to research in topics: Erlotinib & Lung cancer. The author has an hindex of 11, co-authored 24 publications receiving 5474 citations. Previous affiliations of Cinta Pallares include Autonomous University of Barcelona.
Papers
More filters
Journal ArticleDOI
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rafael Rosell,Enric Carcereny,Radj Gervais,A. Vergnenegre,Bartomeu Massuti,Enriqueta Felip,Ramon Palmero,Ramon Garcia-Gomez,Cinta Pallares,Jose Miguel Sanchez,Rut Porta,Manuel Cobo,Pilar Garrido,Flavia Longo,Teresa Moran,A. Insa,Filippo de Marinis,Romain Corre,Isabel Bover,Alfonso Illiano,Eric Dansin,Javier de Castro,Michele Milella,Noemi Reguart,Giuseppe Altavilla,Ulpiano Jimenez,Mariano Provencio,Miguel Angel Moreno,J. Terrasa,Jose Muñoz-Langa,Javier Valdivia,Dolores Isla,Manuel Domine,Olivier Molinier,Julien Mazieres,Nathalie Baize,Rosario García-Campelo,Gilles Robinet,Delvys Rodriguez-Abreu,Guillermo Lopez-Vivanco,Vittorio Gebbia,Lioba Ferrera-Delgado,Pierre Bombaron,R. Bernabé,Alessandra Bearz,Angel Artal,Enrico Cortesi,Christian Rolfo,Maria Sanchez-Ronco,Ana Drozdowskyj,Cristina Queralt,Itziar de Aguirre,Jose Luis Ramirez,Jose Javier Sanchez,Miguel Angel Molina,Miquel Taron,Luis Paz-Ares +56 more
TL;DR: Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations as discussed by the authors.
Journal ArticleDOI
Phase III Study Comparing Cisplatin Plus Fluorouracil to Paclitaxel, Cisplatin, and Fluorouracil Induction Chemotherapy Followed by Chemoradiotherapy in Locally Advanced Head and Neck Cancer
Ricardo Hitt,Antonio Lopez-Pousa,Javier Martinez-Trufero,Vicente Escrig,Joan Carles,Alfredo Rizo,Dolores Isla,M. Eugenia Vega,Juan Luis Gomez Marti,Francisco Lobo,Pedro Pastor,Vicente Valentí,J. Belon,Miguel Ángel Martín Sánchez,Carlos Chaib,Cinta Pallares,Antonio Antón,Andrés Cervantes,Luis Paz-Ares,Hernán Cortés-Funes +19 more
TL;DR: Induction chemotherapy with PCF was better tolerated and resulted in a higher CR rate than CF, and new trials that compare induction chemotherapy plus CRT versus CRT alone are needed to better define the role of neoadjuvant treatment.
Journal ArticleDOI
Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non–Small-Cell Lung Cancer
Mark A. Socinski,Silvia Novello,Julie R. Brahmer,Rafael Rosell,Jose Miguel Sanchez,Chandra P. Belani,Ramaswamy Govindan,James N. Atkins,Heidi H. Gillenwater,Cinta Pallares,L. Tye,Paulina Selaru,Richard C. Chao,Giorgio V. Scagliotti +13 more
TL;DR: Sunitinib has promising single-agent activity in patients with recurrent NSCLC, with an ORR similar to that of currently approved agents and an acceptable safety profile, and further evaluation in combination with other targeted agents and chemotherapy is warranted.
Journal ArticleDOI
Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial.
Rosa Rosell,Radj Gervais,A. Vergnenegre,B. Massuti,E. Felip,Felipe Cardenal,R. Garcia Gomez,Cinta Pallares,J. M. Sanchez,R. Porta,M. Cobo,M. Di Seri,P. Garrido Lopez,A. Insa,F. De Marinis,Romain Corre,M. Carreras,Enric Carcereny,M. Taron,Luis Paz-Ares +19 more
TL;DR: The EURTAC study met its primary endpoint at the interim analysis, and erlotinib as first-line treatment for advanced NSCLC p with EGFR mutations improves PFS, with acceptable toxicity, compared to platinum-based chemotherapy.
Journal ArticleDOI
Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer
Silvia Novello,Giorgio V. Scagliotti,Rafael Rosell,Mark A. Socinski,Julie R. Brahmer,James N. Atkins,Cinta Pallares,R Burgess,L. Tye,Paulina Selaru,E Wang,Richard C. Chao,Ramaswamy Govindan +12 more
TL;DR: The safety profile and time-to-event analyses, albeit relatively low response rate of 2%, suggest single-agent sunitinib on a CDD schedule may be a potential therapeutic agent for patients with advanced, refractory NSCLC.